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Abstract 
Acute myeloid leukemia (AML) is mostly driven by oncogenic transcription factors, 
which have been classically viewed as intractable targets using small molecule inhibitor 
approaches.  Here, we demonstrate that AML driven by repressive transcription factors 
including AML1-ETO and PML-RARα are extremely sensitive to Poly (ADP-ribose) 
Polymerase (PARP) inhibitor (PARPi), in part due to their suppressed expression of key 
homologous recombination genes and thus compromised DNA damage response (DDR).  
In contrast, leukemia driven by MLL fusions with dominant transactivation ability is 
proficient in DDR and insensitive to PARP inhibition.  Intriguing, depletion of an MLL 
downstream target, Hoxa9 that activates expression of various HR genes, impairs DDR 
and sensitizes MLL leukemia to PARPi.  Conversely, Hoxa9 over-expression confers 
PARPi resistance to AML1-ETO and PML-RARα transformed cells. Together, these 
studies describe a potential utility of PARPi-induced synthetic lethality for leukemia 
treatment and reveal a novel molecular mechanism governing PARPi sensitivity in AML.   
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Introduction 
Since its application in BRCA1/2 mutated cancer in just a decade ago, synthetic 
lethal approaches induced by Poly-(ADP-ribose)-polymerase (PARP) inhibitors (PARPi) 
have given renewed enthusiasm to developing anticancer treatments that can specifically 
target cancer cells but spare the normal1,2.  While different models have been proposed to 
explain the molecular mechanisms underlying the synthetic lethality3,4, they mostly 
attribute to the critical function of PARP in a variety of DNA repair processes including 
Base Excision Repair (BER) as a critical sensor of Single Strand Breaks (SSBs)5,6, 
Homologous Recombination (HR) as a mediator for restart of stalled replication forks of 
HR-mediated Double Strand Break (DSB) repair7-9, and Non-Homologous End-Joining 
pathway (NHEJ) by preventing the binding of Ku proteins to DNA ends10. Specifically, 
inhibition of BER impairs SSB repair, which results in accumulation of DSB at the 
replication forks during the S-phase.  While it is also noted that an alternative but not 
mutative exclusive model has also been proposed where PARPi may actually function as 
poisons that result in PARP trapping4, DNA repair and survival of PARP inhibited cells 
seem to be heavily dependent of HR, which are compromised in cancer cells carrying 
BRCA related mutations11-17 leading to their unique susceptibility to PARPi treatment.    
In spite of the promise in breast and ovarian cancer, clinical application of PARPi 
has not widely been translated to different cancers as an effective treatment since 
mutations affecting DNA Damage Response (DDR) genes are not common in other 
malignancies including acute myeloid leukemia (AML)18, which is mainly driven by 
mutated transcription factors such as AML1-ETO, PML-RARα and MLL fusions19.  
Despite the advance in understanding of the genetic basis of the disease, the same 
chemotherapy treatment developed over half a century ago are still used for all AML 
patients, the only exception being Acute Promyelocytic Leukemia (APL) carrying PML-
RARα20.  Due to the high general toxicity, chemotherapy can usually only apply to young 
patients of age under 60, leaving little or no treatment options for the majority of AML 
patients.  In addition, standard chemotherapy only induces long-term complete remission 
in less than 40% of patients and is mostly ineffective in patients carrying mutations in the 
Mixed Lineage Leukemia (MLL) gene20. Therefore there is an urgent need to develop 
better therapeutic strategies for AML.  
Since specific transcriptional programs including those involved in DDR are 
frequently deregulated by various oncogenic transcription factors, we reasoned that 
transcriptional deregulation might represent an alternative mechanism allowing the 
targets of differential DDR for effective leukemia treatments18.  To this end, we 
performed extensive molecular and functional analyses of the effect of PARP inhibition 
on some of the most common forms of AML. Here we show that AML driven by AML1-
ETO and PML-RARα, which suppress the expression of DDR genes, exhibit a 
BRCAness phenotype and can be efficiently targeted by PARPi treatment. On the other 
hand, MLL-driven leukemia is resistant to PARPi but can be sensitized to the treatment 
by genetic or pharmacological inhibition of its downstream target, Hoxa9, which 
mediates effective DDR.  
 
Results 
 
Pharmacological inhibition of PARP selectively suppresses AML1-ETO and PML-
RARα mediated leukemia 
To explore the therapeutic potentials of targeting PARP in acute leukemia, we 
investigated the effect of Olaparib, one of the most commonly used clinical PARPi, on 
clonogenic growth of primary murine hematopoietic cells transformed by the most 
common leukemia associated transcription factors (LATFs) including AML1-ETO, 
PML-RARα, MLL-AF9 and E2A-PBX using the retroviral transduction/transformation 
assay (RTTA), which has been successfully employed to model the corresponding human 
diseases21-24. While a dose-response titration assay identified the in vitro maximal 
tolerable dose at a concentration of up to 1uM Olaparib that exhibited 
undetectable/minimal effects on normal primary bone marrow cells (Supplementary Fig.  
1a-b), the same treatment had striking impacts on primary cells transformed. PARPi 
significantly suppressed colony forming ability of cells transformed by AML1-ETO or 
PML-RARα (by about 90% p<0.001), although it had little impact on MLL-AF9 or E2A-
PBX transformed cells (Fig. 1a-b and Supplementary Fig. 1c-d).  To confirm the 
specificity of the drug, we also reported very similar and selective leukemia suppressive 
effects using a different PARPi, Veliparib (Supplementary Fig. 1e-f), providing an 
independent validation of the potential therapeutic application of PARPi on these 
leukemias.  In order to further demonstrate PARP1 as the major molecular target for the 
observed phenotype, two independently validated shRNAs targeting mouse Parp1 
(Supplementary Fig. 1g-h) were used to replace PARPi in the RTTA.   Consistent with 
the chemical inhibitor studies, both Parp1-shRNAs significantly suppressed the colony 
forming ability of cells transformed by AML1-ETO or PML-RARα (45-70%), but only 
had a modest impact on E2A-PBX and MLL-AF9 transformed cells (Fig. 1c-d and 
Supplementary Fig. 1i), indicating a specific requirement of PARP in leukemic cells 
transformed by AML1-ETO or PML-RARα.  
 
To investigate if PARPi could exert similar inhibitory effects on the 
corresponding human leukemias, we used patient-derived leukemic cell lines carrying 
AML1-ETO (Kasumi), mutated PML-RARα that is resistant to standard ATRA treatment 
(NB4-LR2)24, or MLL-AF9 (THP1) for the inhibitor studies. Analogous to the 
observation in the mouse primary transformed cells, PARPi treatment reduced the colony 
forming ability of Kasumi and NB4-LR2 but did not affect THP1 cells (Fig. 1e-f).  To 
further demonstrate the potential in vivo efficacy, Kasumi, NB4-LR2 and THP1 cells 
were xeno-transplanted into immuno-compromised mice and subjected to the PARPi 
treatment. In spite of being used as a mono-therapy, Olaparib treatment significantly 
delayed the disease onset driven by AML1-ETO from median survival of 55 days to 102 
days (Fig. 1g, Supplementary Fig. 1j, 1m, and Table S1), providing proof-of-principle 
evidence for the application of PARPi in AML1-ETO leukemia.  Strikingly, Olaparib as a 
single agent could also effectively suppress disease onset induced by ATRA-resistant 
APL cells (Fig. 1h, Supplementary Fig. 1k, 1n, and Table S2), highlighting its potential 
use for treatment-resistant APL25.    In contrast, PARPi treatment had no effect on the 
survival of xenograft model transplanted with human THP1 cells carrying MLL-AF9 
(Fig. 1i, Supplementary Fig. 1l, 1o, and Table S3).  To further substantiate these findings, 
we also observed very similar differential in vitro PARPi responses using primary AML 
patient samples carrying the corresponding translocation fusions, in which both AML1-
ETO and PML-RARα (but not MLL fusion) primary human leukemia cells were highly 
sensitive to PARPi  (Supplementary Fig. 1p-q).  Together, these results reveal the 
potential therapeutic utility of PARPi in different subtypes of leukemia driven by specific 
LATFs.   
 
PARPi treatment induces differentiation and senescence 
We next investigated the cellular processes being affected by PARPi in primary 
transformed cells that might explain the inhibitory effect. PARPi treatment on AML1-
ETO and PML-RARα transformed cells in clonogenic assay resulted in their 
morphological differentiation into monocytic/granulocytic lineages (Fig. 2a-b).  These 
results were consistent with the time course measurement of growth and differentiation 
by both morphology and NBT reduction assays, showing that PARPi could slow cell 
growth in general but significantly increased the percentage of differentiation only in 
AML1-ETO and PML-RARα cells (Supplementary Fig. 2a-d). These findings 
corroborate with recent observations of leukemic differentiation induced by excessive 
DNA damage26, suggesting that differential DDR may underlie the contrasting PARPi 
responses.  PARPi treatment was also accompanied by cell cycle G1 arrest (Fig. 2c and 
Supplementary Fig 2e), up-regulation of p53 and p21 (Fig. 2d-e).  Consistently, we also 
detected an increase of p16 expression in AML1-ETO and PML-RARα transformed cells 
(Fig. 2f), which underwent significant senescence upon PARPi treatment (Fig. 2g-h).   
PARPi also induced apoptosis of PML-RARα transformed cells (Fig. 2i and 
Supplementary Fig. 2f). In contrast, none of these effects were observed in E2A-PBX or 
MLL-AF9 transformed cells in spite of a small upward trend in differentiation and 
apoptosis noted in these primary transformed mouse cells upon PARPi treatment (Fig. 
2a-i). To further extend our findings to the corresponding human leukemias, similar 
assays were performed on the human leukemia cell lines and primary human patient 
samples carrying the translocation fusions.  In accord with the results in the mouse 
models, PARPi could effectively induce senescence and apoptosis in Kasumi and NB4-
LR2 but not THP1 (Supplementary Fig. 2g-i); and increased differentiation of primary 
AML cells carrying AML1-ETO and PML-RARα but not MLL fusions (Supplementary 
Fig. 2j-l).  These results consistently suggest a specific requirement of PARP function in 
the leukemic cells transformed by AML1-ETO and PML-RARα. 
 
AML1-ETO and PML-RARα transformed cells show inherent DDR defects 
Although the general rationale behind the PARPi sensitivity is a defect in 
DDR3,4,15,16,27, PARP also has transcriptional functions involved in gene regulation1,28.  
After the biochemical and transcriptional approaches detected no direct biochemical 
interaction (Supplementary Fig. 3a and unpublished mass spectrometry data) and 
transcriptional regulation (Supplementary Fig. 3b-e) between PARP1 and any of these 
fusion proteins, we assayed DNA damage and the kinetics of the DDR in the primary 
transformed cells by analyzing the frequency of Ser-139 phosphorylated γ-H2AX foci, 
which is considered as an early cellular response to DSBs, and the most well established 
chromatin modification linked to DNA damage and repair29. With the exception of E2A-
PBX, untreated AML1-ETO, PML-RARα and MLL-AF9 transformed cells displayed 
significant levels of γH2AX-positive DNA damage foci (with both criteria of >6 and >10 
foci), indicative of ongoing DNA damage or replication stress (Fig. 3a-b, Supplementary 
Fig. 3f). Upon PARPi treatment, both PARPi insensitive (E2A-PBX and MLL-AF9 cells) 
and sensitive cells (AML1-ETO and PML-RARα) showed further inductions of γH2AX 
foci (Fig. 3c, Supplementary Fig. 3g-k), suggesting that PARPi treatment induced DNA 
damage regardless of the onco-fusion proteins expressed by the transformed cells. As 
PARPi have been demonstrated to selectively target HR deficient cells3,15,16, we 
investigated whether PARPi sensitive cells were incapable of effective recruitment of 
Rad51 to DNA damage sites, as a readout of HR efficiency30,31. Upon PARPi treatment 
for 6 hours, E2A-PBX or MLL-AF9 cells, were able to form RAD51 foci (with both 
criteria of >6 and >10 foci), which then returned to basal level after the repair in 24 hours 
(Fig 3c-d, Supplementary Fig. 3g-j,l).  In a stark contrast, no significant Rad51 
recruitment was observed in AML1-ETO or PML-RARα transformed cells (Fig. 3c-d, 
Supplementary Fig. 3g-j, l), in which around 80% of the cells showed γH2AX and Rad51 
foci ratio greater than 2 (Fig. 3e), indicating their HR deficient nature.  The observed 
differential HR deficiency associated with PARPi treatment cannot be due to different 
cell cycle status of these cells, as PARPi exhibited no significant effect on cell cycle 
progression in first 24 hours (Supplementary Fig. 3m) when these assays were performed.  
To further extend our findings to the human disease, human leukemia cell lines carrying 
the corresponding fusions were also subjected to similar DDR assays.  Consistently, we 
observed higher levels of DNA damage in untreated Kasumi and NB4-LR2 cells 
(Supplementary Fig. 3n-o), which also failed to effectively induce Rad51 repair foci upon 
PARPi treatment as compared with THP1 (Supplementary Fig. 3p-r).   
To gain further insights into the differential impacts of LATF on DDR, we 
investigated the expression of the major HR mediators and revealed a decreased 
expression of key HR genes including Rad51, Atm, Brca1 and Brca2 in both AML1-ETO 
and PML-RARα mouse models (Fig. 3f).  To validate these findings in the corresponding 
human leukemias, we analysed the expression array data of these genes in patient 
samples carrying these distinctive LATFs32.  Consistently, we observed very similar 
suppression of a large number of HR mediators in AML1-ETO and PML-RARα human 
leukemic cells as compared with MLL rearranged leukemia (Fig. 3g, Table S4).  These 
results could be independently confirmed by a second set of array data from different 
patient cohorts33 (Supplementary Fig. 3s).  We also further validated the results of two 
key HR mediators, RAD51 and BRCA2, at the protein level by Western blot using mouse 
primary leukemic cells transformed by the corresponding fusions (Fig. 3h), although the 
differential expression of RAD51 was milder than BRCA2, which were in line with the 
RNA expression data (Fig. 3f).  These results consistently suggest that suppression of HR 
genes is a distinctive feature shared by PARPi sensitive AML1-ETO and PML-RARα 
transformed cells.  To further assess the direct effect of these fusion proteins on DNA 
repair efficiency, we performed both plasmid end-joining assay34 and HR reporter 
assay35.  Nuclear extracts from E2A-PBX and MLL-AF9 transformed cells could 
efficiently repair DSB and produced significantly higher total numbers of colonies as 
compared to those by AML1-ETO and PML-RARα transformed cells (Fig. 3i). 
Moreover, in contrast to E2A-PBX and MLL-AF9, most of the end-repairs by AML1-
ETO or PML-RARα nuclear extracts were mis-matched (Fig. 3j).  Consistently, we also 
observed significant suppression of HR efficiency upon expression of AML1-ETO or 
PML-RARα as opposite to a small notable and significant increase of HR efficiency by 
MLL-AF9 (Fig. 3k). Therefore these data indicate that leukemic cells driven by AML1-
ETO and PML-RARα had a reduced ability to repair DSBs and that the repairs 
accompanied with an increased error rate, which may form the basis for their increased 
PARPi sensitivity.  
 
Induction of Hoxa9 expression by MLL fusions modulates PARPi sensitivity 
To gain novel mechanistic insights regulating the PARPi sensitivity, we analysed 
PARPi-resistant MLL leukemic cells, which showed a high basal level of phosphorylated 
γH2AX (Fig. 3a-b) but were able to efficiently recruit Rad51 to the DNA damage foci 
(Fig. 3c-d) and survived PARPi treatment (Fig. 1-2), suggesting HR competency.  In 
contrast to AML1-ETO and PML-RARα19,23, MLL fusion proteins recruit chromatin 
remodeling enzymes and transactivation complexes culminating in the expression of 
critical downstream genes, including the homeodomain transcription factor 
HOXA919,36,37, which has been previously identified as one of the single most critical 
independent poor prognostic factors associated with inferior treatment response in AML38 
and its suppression has been linked to the drug resistant phenotype in glioblastoma39,40.  
Consistently, we could observe specific and differential activation of Hoxa9 by MLL 
fusion in our mouse models and independent human patient data (Supplementary Fig. 4a-
c). Thus we hypothesized that the PARPi resistance exhibited by MLL-AF9 transformed 
cells might be dependent of its ability to activate Hoxa9 expression. To this end, we 
assessed the functional requirement of Hoxa9 in conferring PARPi resistance in MLL-
AF9 transformed cells using RTTA in combined with a Hoxa9 knockout mouse model.  
Consistent with the previous report23,41,42, Hoxa9 knockout had relatively modest effect 
on both in vitro and in vivo transformation mediated by MLL-AF9 its spite of a more 
mature phenotype and a slightly reduced colony forming ability as compared with their 
wild type counterpart41 (Fig. 4a-c and Supplementary Fig. 4d-g). Strikingly, ablation of 
Hoxa9 expression sensitized MLL-AF9 transformed cells to PARPi treatment, which 
resulted in a significant suppression of colony forming ability and differentiation of 
MLL-AF9 transformed cells (Fig. 4a-c and Supplementary Fig. 4e-f).  In contrast, Hoxa9 
knockout had a modest effect on E2A-PBX transformed cells, which have previousuly 
been shown as an Hoxa9 independent oncofusion23,43 (Fig. 4a-c and Supplementary Fig.  
4d-e). We also observed induction of senescence in MLL-AF9 Hoxa9-/- transformed cells 
upon PARPi treatment (Fig. 4d-e), which is consistent with the role of Hoxa9 in 
suppressing cellular senescence23, a common endpoint of excessive DNA damage.  These 
data indicate that Hoxa9 may play a key role in mediating PARPi resistance in MLL 
transformed cells, and its suppression in combination with PARPi may represent a novel 
avenue for targeting MLL leukemia. To this end, we tested the in vivo efficacy of this 
approach using MLL-AF9 full-blown leukemic cells derived from primary transplanted 
mouse, which closely mimic the advanced clinical stage of the corresponding human 
disease22. As expected, Olaparib treatment did not have any significant effect on mice 
transplanted with wild type MLL-AF9 leukemic cells (Fig 4f, Supplementary Fig. 4h and 
Table S5).  In contrast, while Hoxa9 deficient MLL-AF9 leukemic cells could efficiently 
induce leukemia, they were highly sensitive to PARPi treatment, which significantly 
delayed the disease latency (Fig 4g, Supplementary Fig. 4h and Table S6), indicating a 
critical function of Hoxa9 in mediating PARPi resistance in MLL leukemia. 
To further demonstrate the role of Hoxa9 in mediating PARPi resistance, we also 
employed a gain of function approach by over-expressing Hoxa9 in PARPi sensitive 
AML-ETO and PML-RARα leukemic cells. As expected, AML1-ETO and PML-RARα 
cells transduced with the vector control remained sensitive to PARPi treatment.  
Interestingly, forced expression of Hoxa9 conferred PARPi resistant to AML1-ETO and 
PML-RARα cells without affecting the expression of the fusions (Fig. 4h-j and 
Supplementary Fig. 4i-j); AML1-ETO or PML-RARα cells co-transduced with Hoxa9 
could still form compact colonies with immature myeloblast phenotypes upon PARPi 
treatment. Hoxa9 expression also suppressed PARPi-induced senescence in AML1-ETO 
and PML-RARα cells (Fig 4k-l).  Together with the loss of function data, these results 
strongly suggest that Hoxa9 plays a key role in mediating PARPi resistance in leukemic 
cells.  
 
Hoxa9 activates expression of HR gene expression, promotes Rad51 foci formation 
and  DNA repairs   
Given that the primary effect of PARPi treatment is on DNA repair, we analysed 
the effect of Hoxa9 in mediating DDR in transformed cells. In contrast to AML1-ETO 
and PML-RARα transformed cells, which were incompetent to mount significant Rad51 
repair foci at DNA damage sites upon PARPi treatment  (Fig. 3c), Hoxa9 over-expression 
conferred on these cells the ability to efficiently recruit Rad51 to DNA damage foci (Fig. 
5a-b). Over-expression of Hoxa9 had modest effects on E2A-PBX or MLL-AF9 
transformed cells, which already showed efficient recruitment of Rad51 (Fig. 5a-b). 
Conversely, suppression of Hoxa9 expression resulted in a significant impairment of 
Rad51 recruitment in MLL-AF9 transformed cells (Fig. 5c-d), leading to the hypothesis 
that Hoxa9 might be an upstream regulator of Rad51. To this end, we analyzed the 
expression array data of known Hoxa9 downstream targets in primary transformed 
myeloid cells44,45. The gene set enrichment analysis (GSEA) and gene ontology analysis 
(GO) revealed that genes involved in DNA repair, especially DNA repair with 
homologous recombination, were significantly enriched in HOXA9 responsive gene set 
(Fig. 5e, Supplementary Fig. 5a-b, and Table S4).  These results were also confirmed by 
RT-qPCR in Hoxa9 knockout MLL-AF9 transformed cells (Supplementary Fig.5c).   
Among them were key HR genes including Rad5112,30,31, which was further validated in 
the primary transformed cells by both Hoxa9 over-expression (Fig. 5f) and knockout 
approaches (Fig. 5g).  The regulation of RAD51 and BRCA2 expression by Hoxa9 in 
MLL-AF9 cells were also demonstrated at the protein level, where the expressions of 
these two proteins were significantly diminished in the absence of Hoxa9 (but not β-
catenin control) (Fig. 5h).  While these results consistently suggest an important 
involvement of common HR genes (e.g., Rad51 and Brca2) in mediating differential 
PARPi responses exhibited by different LATFs, there are also likely other HR targets 
uniquely regulated by individual LATFs that also contribute to their differential 
responses. Finally, to demonstrate a direct involvement of HOXA9 in DDR, HR-reporter 
assays further revealed an enhanced HR efficiency by Hoxa9 expression as opposite to a 
compromised HR response upon its suppression (Figure 5i). These data strongly suggest 
that Hoxa9 confers resistance to PARPi in part by activating DDR transcription 
programs.  
 
 
Targeting PARPi resistant AML with a combination approach 
 
While there is not yet chemical inhibitor that can directly target Hoxa9, inhibitors 
are available to target its upstream regulators and essential co-factors, including GSK3, 
which mediates the phosphorylation of CREB/CBP required for Hox transcriptional 
functions46. We and others have previously shown that GSK3 inhibitor (GSKi) such as 
LiCl and LiCO3 were effective in suppressing the transcriptional activity of Hox and 
targeting MLL pre-leukemic stem cells (pre-LSC), but not the advanced stage MLL LSC 
that acquired resistance in part due to the activation of canonical Wnt/β-catenin pathways 
and were capable of inducing leukemia with a much shorter latency22,46,47.  To further 
explore the potential application of PARPi on MLL leukemia, we assessed the effect of 
PARPi in combination with GSK3i (LiCl), on both MLL pre-LSC and MLL LSC 
enriched populations that exhibited contrasting GSKi sensitivity and disease latency22.  
As expected, the application of previously defined optimal concentration of LiCl 
(Supplementary Fig. 6a)22,46,47 significantly suppressed the colony forming ability of 
MLL pre-LSC, but not MLL LSC (Fig. 6a,c, and Supplementary Fig. 6b-c).  
Interestingly, its combination with otherwise non-effective PARPi treatment led to 
further increased growth inhibition (Fig. 6a,c), which inversely correlated with 
transcriptional activity of Hoxa9 as assessed by the expression of its downstream target, 
c-myb (Fig. 6b,d).  More strikingly, while individual PARPi or LiCl treatment was 
ineffective on MLL LSC, their combination dramatically suppressed leukemic cell 
growth and induced differentiation of MLL LSC (Fig. 6c, e, f).  To further demonstrate 
the in vivo efficacy, pretreated MLL LSC were transplanted into syngeneic mice, and 
subjected to Olaparib, LiCO3, or their combined treatments (Figure 6g). As expected, 
mice transplanted with control MLL-AF9 cells succumbed to leukemia within 8 weeks 
(Fig. 6g, Supplementary Fig. 6d-e, and Table S7).  PARPi or GSK3i treatment alone did 
not significantly extend the survival (Fig. 6g, Supplementary Fig. 6d-e, and Table S7).  
Strikingly, the combined PARPi and GSK3i treatment suppressed leukemia development 
and all the mice still survived within the 80 days of observation period (Fig. 6g, 
Supplementary Fig. 6d-e, and Table S7), highlighting the therapeutic potential of the 
novel combined treatment for MLL leukemia.   
To investigate if a similar treatment could also be effective in the corresponding 
human leukemia, THP1 cells derived from the patient with MLL-AF9 fusion were also 
tested.  As expected, Olaparib alone was ineffective and only modest suppression was 
observed with LiCl treatment (Supplementary Fig. 6f-g).  However in combination, LiCl 
could sensitize PARPi-resistant THP1 cells to the PARPi treatment resulting in 
significant growth suppression and differentiation of the leukemic cells (Supplementary 
Fig. 6f-g).  To further strengthen our findings in the relevant clinical setting, we 
performed the same treatments on two independent primary human patient samples 
carrying MLL fusions (i.e., patients AML1 and AML2). While limited inhibition was 
exhibited by individual treatments, their combination showed consistent and significant 
synergistic effects in suppressing growth and promoting differentiation of both primary 
MLL leukemic cells (Fig. 6h-k). Finally, to monitor and further demonstrate the in vivo 
treatment efficacy in primary, we labelled the primary MLL leukemic cells from patient 
AML1 with a luciferase reporter prior their transplantation into NSG mice for drug 
treatments.  By in vivo imaging, we observed a rapid disease development as early as 4 
weeks post-transplant in the untreated control (Fig. 6l, Supplementary Fig. 6h).  A similar 
rate of disease progression was also observed in cohorts receiving single drug treatments 
although LiCO3 treated group might exhibit an even faster rate of leukemic growth (Fig. 
6l, Supplementary Fig. 6h).  In contrast, PARPi/LiCO3 combination treatment 
significantly prohibited leukemic cell growth in vivo (Fig. 6l, Supplementary Fig. 6h).  
Following the long-term disease development, mice received single drug treatment 
succumbed to leukemia with a similar phenotype and disease latency as the control group 
(Fig. 6m, Supplementary Fig. 6i-j, Table S8).  Strikingly, the combination treatment 
significantly suppressed leukemia development and none of the tested subjects 
succumbed to leukemia throughout the observation period (Fig. 6m, Supplementary Fig. 
6i-j).  Together, these independent results from mouse models and primary human 
xenograft models provide the first proof-of-principle pre-clinic evidence for a novel 
effective therapeutic strategy based on a combined PARPi and GSK3i treatment for MLL 
leukemia.  
 
 
Discussion 
In spite of the lack of genetic mutations directly affecting DDR genes, we provide 
molecular evidence and preclinical data showing the potential utility of PARPi-mediated 
selective killing of leukemic cells carrying specific oncogenic transcription factors 
(Supplementary Fig. 7).  This appears to be due to the differential impacts on these 
transcription factors on the expression of critical DDR genes involved DDR48-52. In 
addition to the discovery of strong PARPi sensitivity exhibited by AML1-ETO and PML-
RARα transformed cells, we also demonstrate for the first time that Hoxa9, an 
independent poor prognostic factor in AML38 and a key downstream target of MLL-
fusions53, can activate a potential back-up DDR pathway, which may allow leukemia 
cells to overcome PARPi.  This finding may also in part explain the previously reported 
S-phase checkpoint dysfunction of MLL-rearranged leukemic cells showing radio-
resistant DNA synthesis and chromatid-type genomic abnormalities54.  
Emerging evidence suggests that various Hox proteins may be involved in DNA 
repair55,56. HoxB7 interacts directly with PARP-1 and the complex DNA-PK-Ku80-Ku70 
enabling NHEJ pathway55, whereas HoxB9 promotes HR by inducing TGFβ, which in 
turn enhances ATM activation and ATM-dependent response in breast cancer cell lines56.  
Our data indicate that Hoxa9 mediates expression of critical DDR genes to stimulate HR 
and recruitment of Rad51 to DNA damage foci in response to PARPi treatment. 
Consistent with its putative role in mediating drug resistant in glioma43,44, we further 
demonstrate that Hoxa9 over-expression rescues AML1-ETO and PML-RARα cells from 
PARPi treatment, whereas Hoxa9 KO makes MLL-AF9 sensitive to PARPi, revealing a 
novel function of Hoxa9 as a major player in governing PARPi resistance in MLL 
leukemia.    
 In line with a classical model of DDR barrier in cancer development57, a recent 
study by Takacova et al. demonstrated that inactivation of the DDR barrier through 
ATM/ATR inhibitors accelerated leukemia driven by a tamoxifen-inducible MLL 
fusion58. On the other hand, Santos et al. have elegantly shown that total genetic ablation 
of critical DDR genes such as MLL4, ATM or BRCA1, instead of accelerating, inhibited 
MLL-driven leukemogenesis by inducing leukemic differentiation59.  These results 
suggest dual roles of some of the key DDR players such as ATM in promoting and 
suppressing MLL leukemia, which may be dosage and context dependent.   Interestingly, 
Hoxa9 that predominately drives leukemic growth and PARPi resistance is largely 
dispensable for normal development23,42,60, highlighting its potential as a therapeutic 
target. As a proof-of-principle experiment, we further demonstrate that the combined use 
of PARPi together with the GSK3i that targeted the transcriptional function of 
Hoxa922,46,47 can achieve selective killing of otherwise PARPi-resistant MLL leukemic 
cells, revealing a potentially novel venue for overcoming PARPi-resistance in leukemia 
(Supplementary Fig. 7).    
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Materials and Methods 
 
Retroviral Transduction/Transformation Assay (RTTA) 
RTTA was performed on primary murine hematopoietic cells as described21. c-Kit 
positive progenitor cells were isolated from wild type Ly5.1 mouse bone marrow, and 
cultured overnight in R10 medium [RPMI 1640 containing 10% FCS, 100U/mL 
penicillin and 100µg/mL streptomycin] supplemented with 20ngml-1 stem cell factor 
(SCF), 10ngml-1 interleukin (IL)-3, and 10ngml-1 IL-6. Transduction using concentrated 
viral supernatant expressing the oncogene of interest was carried out by centrifugation 
(spinoculation) at 800g at 32 ºC for 2 hours in the presence of 5μg ml-1 polybrene 
(Sigma-Aldrich). Cells were subsequently plated in 1% methylcellulose medium (M3231; 
Stem Cell Technologies) containing 20ngml-1 SCF, 10ngml-1 IL-3, 10ngml-1 IL-6 and 
10ngml-1 granulocyte macrophage colony-stimulating factor (GM–CSF) and appropriate 
selection antibiotic. Colonies were counted after 7 days of culture and replated every 6-7 
days at 5x103-1.5x104 cell density. Re-plating was performed weekly to generate primary 
cell lines for further analysis. After the third or fourth round of plating, cells were 
cultured in R20/20 medium (RPMI 1640, 20% FCS, 20% WEHI-conditioned medium, 2 
mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin) supplemented with 
20ngml-1 stem cell factor (SCF), 10ngml-1 interleukin (IL)-3, and 10ngml-1 IL-6 to 
establish cell lines. All recombinant murine cytokines were from PeprotechEC. 
 
Cell culture  
NB4-LR2 and THP1 cell lines (kindly provided by Dr Arthur Zelent and Professor Mel 
Greaves respectively) were cultured in RPMI (Invitrogen) supplemented with 10% 
selected FBS (R10), 2mM L-Glutamine. Kasumi cell line (kindly provided by Dr Olaf 
Heidenreich) was cultured in RPMI-Hepes modified (Sigma) supplemented with 20% 
selected FBS and 2mM L-Glutamine (R20). Cell lines were validated by qPCR for their 
respective oncogenes. NIH3T3 and GP2 cell line was cultured in DMEM (Invitrogen) 
supplemented with 10% selected FBS and 2mM L-Glutamine. Human primary AML 
cells were cultured in IMEM (Invitrogen) supplemented with 10% PBS, 2mM L-
Glutamine, 10ng/mL each of human cytokines, IL3, IL6, SCF, FLT3 ligand, and TPO.  
Cells were kept at 37°C and 5%CO2. Use of human primary cells was approved by 
King’s College London committee and consents of the patients were obtained. 
 
In vitro drug treatment 
Most of the inhibitor studies on mouse cells were carried out by plating 3-5x103 cells in 
1% methylcellulose medium containing 20ng ml-1 SCF, 10ng ml-1 IL-3, 10ngml-1 IL-6 
and 10ng ml-1 GM–CSF in the presence of 1µM Olaparib (LC Laboratories), 1µM 
Veliparib (Abbott) or 8mM Lithium Chloride (LiCl, Sigma) at the concentrations as 
indicated in the Results section. Colonies were scored 6-7 days after plating.  For other in 
vitro studies, mouse leukemic cells and primary AML cell lines were subjected to 
continuously Olaparib (1µM) or LiCl (8mM) treatment in liquid culture for whole 
duration as indicated in the figures or figure legends. For human leukemic cell lines, 
experiments were performed as described above with 5µM Olaparib.  
 
Flow cytometric analysis 
Flow cytometry analyses of mouse leukemic cells for both in vitro and in vivo 
experiments were performed as previously described61 using mouse specific anti-CD11b 
(Mac-1) (clone M1/70), anti-Gr1 (clone RB6-8C5), anti-c-Kit (clone 2B8), anti-CD45.1 
(clone A20) and anti-CD45.2 (clone 104) antibodies from BioLegend.  For humanized 
mouse model, the engrafted human donor cells were analysed using anti-human CD45 
(clone H130) and CD33 (clone WM53). 
 
Cell cycle analysis 
For each assay 1x105 cells were collected, washed in PBS and fixed in 70% cold ethanol. 
After re-hydration with PBS and centrifugation at 500g for five minutes, the cells were 
incubated with a solution of PBS containing 1% FCS, 40ug/ml RNAse and 500ug/ml 
propidium iodide solution (Sigma-Aldrich) in the dark for 30 minutes at 37° C. Samples 
were then analyzed at the FACS LSRII (BD Biosciences Pharmingen). DNA peaks were 
analyzed with FACS Diva. 
 
Annexin V staining 
For each assay 1x105 cells were collected, washed in PBS and re-suspended in Annexin 
V binding solution (25mM Hepes, 140mM KCl, 2.5mM CaCl2 pH 7.2). After 
centrifugation at 500g for five minutes the cells were incubated with the Annexin V 
Binding solution containing 0.25 ug/ml mouse anti Annexin V-FITC antibody (Biolegend 
640906)  and 1ug/ml propidium iodide in the dark for 30 minutes at 4°C. Samples were 
then washed in PBS analysed at the FACS LSRII (BD Biosciences Pharmingen) with 
FACS Diva. 
 
Beta galactosidase staining 
Cells were cytospun onto a glass slide at 400g for 5 minutes and then fixed for 10 
minutes with 2% formaldehyde/0.2% glutaraldehyde (Sigma Aldrich). Cells were then 
washed with PBS, and then incubated at 37°C for at least 2 hours with a staining solution 
(30mM Citric Acid/Phosphate buffer, 5mM K4Fe(CN)6, 5mM K3Fe(CN)6, 150mM NaCl, 
2mM MgCl2, 1mg/ml X-Gal) (All reagents from Sigma-Aldrich)62. Cells were counted in 
at least 5 fields for each slide, for a total of over 100 cells. The percentage of senescent 
cells was calculated by the percentage of the number of blue cell in the field.  
 
Immunofluorescence staining of γH2AX and RAD51 
Cells were cytospun onto a glass slide at 400g for 5 minutes and then fixed for 30 
minutes in 4% PFA and permeabilized and blocked in 0.8% Tx-100, 10% FBS/1% BSA 
(Sigma-Aldrich) in PBS for 15 min at room temperature. Mouse anti mouse γH2AX 
(ser139) (Upstate clone JBW301 #05-636) and rabbit anti mouse RAD51 (Santa Cruz  
Biotecnology H92 #sc-8349) were diluted in TBS containing 10%FBS/1%BSA and 
incubated overnight at 4C. Slides were then washed three times with PBS and 
subsequently incubated with 1:200 donkey anti mouse DL 488 (Jackson/Stratech 715-
485-150) and 1:200 goat anti-rabbit Cy3  (Jackson/Stratech 111-165-144) in  TBS 
containing DAPI 0.2ug/ml, 10%FBS, 1%BSA for 1 hour at room temperature in the dark. 
Slides were then washed five times at 10 min each with PBS. Slides were briefly washed 
in water and air-dried prior to mounting with Mowiol-DABCO and a coverslip. Cells 
were counted in at least 5 fields for each slide, for a total of over 100 cells per condition.  
 
May-Grunwald-Giemsa staining 
1x105 cells were cytospun for 5min at 300g onto glass slides. Slides were then stained 
with May-Grunwald solution (Sigma-Aldrich) for 3 min at room temperature. After 
washing in water, they were incubated for 20min in Giemsa solution (Sigma-Aldrich) 
(1:20 in water). Slides were washed again in water before being mounted with Mowiol. 
Cells were counted in at least 5 fields for each slide, for a total of over 100 cells per 
condition. 
 
Nitro blue tetrazolium (NBT) reduction assay 
NBT reduction assay were performed to determine myeloid differentiation.  0.1% of NBT 
(final concentration) was added to the liquid culture or semi-solid methocult and 
incubated at 37oC CO2 incubator for 3hrs and 12hrs, respectively. Cells were then washed 
in PBS and the differentiated cells were indicated by the deposition of dark blue insoluble 
formazan (NBT positive cells) and the percentage of differentiated cells were counted 
under microscopy. At least 200 cells were counted in most of the cases. 
 
Mouse Parp1 Knockdown 
Scramble or mouse Parp1 targeting sequences were cloned into pSuper-Retro-Puro 
retroviral vector (OligoEngine). The target sequences for mouse Parp-1 gene 
(NM007415.2) are TAAAgAAGCTGACGGTGAA (targeting the position 2014-2032, 
sh#A)63, GCCGCCTACTCTATCCTCA (targeting the position 2014-2032, sh#D). The 
scramble sequence is GCGAAAGATGATAAGCTAA. 
 
Expression of mouse Parp1 shRNA in NIH3T3 cell line 
1.6x105 cells were plated in each well of 6 well-plates mm and allowed to attach for 6hrs 
when the cells were infected with 200µl of concentrated virus expressing i) the empty 
vector, ii) the scramble or iii) shRNA against mouse Parp1 and 5ug/ml of polybrene in a 
final volume of 2 ml. After 24 hours, the medium was replaced fresh one containing 
1.5µg/ml puromycin (Invitrogen) for a 3-days selection. Cells were then collected for 
RT-qPCR and Western Blot analysis.  
 
Western blot analysis 
Cells were collected by centrifugation and cell pellet was suspended in lysis buffer 
(0.02% SDS, 0.5% Triton, 300mM NaCl, 20mM Tris-HCl pH 7.5, 1mM EDTA, 1mM 
DTT, 10mM NaF, 2mM Na3VO4) containing 1X protease inhibitors (Roche) and 
incubated on ice for 30min. Following centrifugation at 16000 g for 15 min at 4°C, the 
supernatant containing total cell extract was collected and kept at -80°C. Proteins from 
cell extracts were quantified using OD660nm Assay (Pierce).  10µg of cell extracts were 
loaded on a 12% polyacrylamide gel and then electrophoretically transferred onto a 
Hybond-PVDF membrane (GE Healthcare). The membrane was incubated for 1h at room 
temperature in blocking buffer (TBS-T containing 8% skimmed milk) to block non-
specific protein binding and then incubated at 4°C overnight with the primary antibody, 
listed in Table S9. Mouse BRCA2 antibody was kindly provided by Dr. Lee. Following 
four washes with TBS-T, the membrane was incubated for 1 hour with the HPR-
conjugated antibody, anti-mouse or anti rabbit (Jackson ImmunoResearch) diluted in 
blocking buffer. Antibody binding was visualized using the ECL Prime Western blotting 
detection system (GE Healthcare).  
 
Immunoprecipitation assay 
Cells were lysed as above (with a reduced NaCl concentration to 200mM).  The 500ug of 
total cell lysates were incubated with 1ug anti-FLAG antibody at 4°C  for 12 hrs with 
rotation.  Then protein-A cojugated beads were added to precipitate the protein complex 
and incubated at 4°C  for 1 hr with rotation.  Beads were then washed 5 times with 
reduced NaCl cell lysis buffer and eluted by 50ul 2% SDS-Tris buffer.  
 
Real time Quantitative PCR 
RNA was extracted by using a kit from Fermentas and was reverse transcribed using 
Super-Script III from Invitrogen. qPCR was performed by using SYBR Green or Taqman 
probes on an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems) using 
primers listed in Table S10. GAPDH is used a house keeping gene. Relative Expression 
levels were calculated using the 2-∆∆CT method64.  
 
In vivo plasmid end-joining assay 
In vivo plasmid end-joining assay was performed as described65. Briefly a Double Strand 
Break (DSB) is generated in the LacZ gene sequence of the plasmid PUC18 by EcoRI 
digestion. Nuclear extracts from pre-leukemic cells carrying the above mentioned onco-
fusion proteins were obtained by using the Nuclear Extraction Kit (Pierce).  2µg of 
PUC18 plasmid was digested with EcoRI (Fermentas), dephosphorylated (Fermentas), 
separated on agarose gel 1% and extracted using a column based method (Qiagen). 5ug 
nuclear extracts were then incubated in NHEJ buffer (50mM Trietanolammine HCL 
pH7.5, 60mM Potassium Acetate, 0.5mM Magnesium Acetate, 250uM dNTPs, 10mM 
ATP, 5mM dTT, 500ug/ml BSA) for 5min at 37°C.  250ng of digested- 
dephosphorylated plasmid were then added to the reaction in 50-100µl final volume and 
incubated for 24hrs at 18°C. Next day, the DNA was purified using a column based 
method (Qiagen) and 30ng were used to transform E. Coli and plate them on LB-agar 
plates + 160ug/ml X-Gal (Sigma-Aldrich) and 1mM IPTG (Sigma-Aldrich). Colonies 
were counted and plotted as shown in Fig. 3i/j. The percentage of misrepair was 
calculated as the percentage of blue colonies versus total number of colonies. 
 
Homologous Recombination Assay 
U2OS cells containing a single copy of the DR-GFP reporter (U2OS-DR) was kindly 
provided by Dr Maria Jasin. 0.5×106 U2OS-DR cells were plated into 6-well plate. After 
24 hours, cells were co-transfected with I-SceI expression (pCBASce, 1.25µg), 
oncogenes of interests (1.25µg) and RFP constructs (0.2µg) using Lipofectamine 2000 
(Invitrogen) according to the manufacture’s protocol. Percentage of GFP-positive cells 
was measured by flow cytometry three days after transfection and normalized against 
percentage of RFP for transfection efficiency.  Relative HR efficiency was then 
normalized to empty vector. 
 
In vivo experiments 
All the experimental procedures were approved by King’s College London committee 
and conform to the UK Home office regulations.  
 
We established humanized models of AML1-ETO and PML-RARα leukemia in sub-
lethally irradiated NOD/SCID/IL2Rg-/- (NSG, 1 dose 200 RADs) by transplanting 2x106 
Kasumi (intra-femoral, IF) and 1x105 NB4-LR2 or 1x105THP1 (intravenous, IV) cells. 
The day after the transplantation, mice were split into two groups and given intra-
peritoneal injections of vehicle (10% HBC) or Olaparib (25mg/kg in 10% HBC) daily for 
2-4 weeks. The maximum tolerable dose was calculated by in vivo dose-response 
experiments. Mice were monitored daily until they developed symptoms of leukemia, 
when they were culled and bone marrow, spleen and liver harvested and analyzed by 
FACS. The engraftment of human donor cells was defined as human CD45/CD33 double 
positive by FACS. 
 
For Hoxa9 KO studies, we intravenously injected 106 MLL-AF9 leukemic cells (wild 
type or Hoxa9-/- background) together with 2x105 bone marrow rescue cells into lethally 
irradiated C57Bl/6 mice (2 doses of irradiation 550RADS each) for disease development. 
For drug studies, the control cohort received vehicle (10% 2-Hydroxpropyl-beta-
cyclodextrin, HBC, Sigma-Aldrich) and the PARPi treatment group received daily 
Olaparib 50mg/kg in 10% HBC for two-four weeks.  
 
For mouse MLL-AF9 LSC in vivo studies involving PARPi and GSK3i, MLL-AF9 LSC 
were pretreated in R20/20 with 4mM LiCl or 1uM Olaparib or combination for 3 days. 
Equal number 0.2×106 of live cells were transplanted into sublethally irradiated C57Bl6 
mice.  Continuous Olaparib and LiCO3 treatment was commenced on the day after 
irradiation and injection of cells. Mice were given 0.4% lithium carbonate containing diet 
(Harlan Laboratory) along with Olaparib by IP every other day for 4 weeks.  The 
engraftment of mouse donor cells was defined as CD45.1+/ CD45.2- by FACS. 
 
For in vivo experiment with primary AML samples, 105 AML1 cells transduced with 
firefly luciferase expressing plasmid were transplanted via by IF into the right femur of 
the NSG mice. Three days after transplantation, mice were supplemented with 0.4% 
LiCO3 containing diet and treated with Olaparib as described above for alternative day 
until day 21.  After day 21, mice were maintained on 5 days of lithium carbonate diet and 
alternated with 2 days regular diet and water for 2 additional weeks.  From day 21, the 
tumor burdens of the animals were detected using IVIS Lumina II® (Caliper) with 
software Living Image® Verion 4.3.1.  Briefly, 100µl of 30mg/mL luciferin were 
injected into the animals by IP. 10 minutes after injection, the animals were maintained in 
general anaesthesia by isoflurane and put into the IVIS chamber for photography and 
detection of photon emission (large binning, F=1.2, exposure time: 3 mins).  The tumor 
burden were measured and quantified by the same software as instructed.  The animals 
were culled when the tumor burden was 10e8 photon per second or higher.   
 
Microarray and Bioinformatic Analysis 
Expression profiles of AML1-ETO (22 samples, cluster13), APL (18 samples, cluster 
12), MLL (11 samples, cluster 16) patients were obtained from GEO accession: 
GSE115932. The data was supported by performing additional gene expression analysis 
on independent set of published microarray dataset from GSE6891 containing AML1-
ETO (37 samples), APL (25 samples), and MLL (35 samples) leukemia samples. All 
intensity values was adjusted, normalized and summarized in log2 scale using 
Bioconductor Affy66 (background correction: rma; normalization: quantiles;  
summarization:  median polish). The differential expression analysis of AML1-ETO and 
APL against MLL were performed using Bioconductor Limma. The p-values were 
calculated by paired two-tailed t- Test. The selected genes’ expression of AML-ETO, 
APL and MLL were plotted in box-whisker plot using Prism5 software.  Gene set 
enrichment analysis (GSEA) was performed as described67 using published datasets 44,45.  
 
Statistical Analysis 
All the experimental results were analyzed using unpaired two-tailed Student’s t-Test, 1-
way or 2-way ANOVA, as indicated in figure legends. Groups that are statistically 
compared shared a similar variance as shown in the figures. p-values lower than 0.05 
were considered statistically significant. The log-rank test was used to compare survival 
curves.  
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Figure Legends  
Figure 1: PARPi targets AML1-ETO and PML-RARα leukemic cells in vitro and in 
vivo.  
a) Relative number of colonies of leukemic cells surviving to PARPi, Olaparib. The 
number of colonies was acquired after seven days of Olaparib treatment in each round 
and data was normalized against the vehicle control. Data represents means of six 
independent experiments ± SD. 1-way ANOVA test was performed between vehicle and 
Olaparib treated cells for each condition ***p<0.001. b) Representative colony 
morphology with or without Olaparib treatment. Images were acquired using a phase 
contrast microscope (magnification 40X). c) Relative number of colonies of oncogene-
induced leukemic cells transduced either with empty vector or shRNA targeting Parp1. 
The number of colonies was normalized against  empty vector control. Data represents 
means of at least three independent experiments ± SD. 2-way ANOVA test was 
performed between empty vector and i) sh-Parp1-A and ii) sh-Parp1-D, *p<0.05, 
**p<0.01, ***p<0.001. d) Representative colony morphology of leukemic cells 
transformed by indicated oncoproteins and transduced with empty vector/Parp1 shRNA. 
Images were acquired using a phase contrast microscopy (magnification 40X). e) 
Relative number of colonies of human leukemic cell lines Kasumi (AML1-ETO), NB4-
LR2 (PML-RARα) and THP1 (MLL-AF9) grown in methylcellulose for 7 days with 
5µM Olaparib. The number of colonies after PARPi treatment was normalized against the 
untreated control. Data represents means of three independent experiments ± SD. 1-way 
ANOVA test was performed between untreated and Olaparib treated cells for each 
condition ***p<0.001. f) Colony morphology of human leukemic cell lines treated with 
PARPi (phase contrast microscopy, magnification 40X). Representative pictures are 
shown. g) Kaplan-Meier survival curve of NSG mice transplanted with Kasumi cell lines 
(vehicle n=6, Olaparib n=5, pooled from two independent experiments). Log-rank 
(Mantel-Cox) test was performed between the two curves, p< 0.01. h) Kaplan-Meier 
survival curve of NSG mice transplanted with NB4-LR2 cell line (vehicle n=5, Olaparib 
n=10). Log-rank (Mantel-Cox) test was performed between the two curves. p< 0.05. i)  
Kaplan-Meier survival curve of NSG mice transplanted with human THP1cells (vehicle 
n=5, Olaparib n=5). Log-rank (Mantel-Cox) test was performed between the two curves, 
p=1. 
 
Figure 2: PARPi induces differentiation, senescence, and apoptosis of AML1-ETO 
and PML-RARα leukemic cells 
a) Giemsa-MacGrunwald staining of leukemic cells showing myeloid differentiation in 
AML1-ETO and PML-RARα leukemic cells upon treatment with PARPi. b) 
Quantification of morphologically differentiated cells relating to fig. 2(a). 1-way 
ANOVA was performed between vehicle and PARPi treated cells ***p<0.01. c) Cell 
cycle analysis of leukemic cells after 48-72hrs of continuous PARPi treatment. Relative 
percentage of cells in G0-G1, S and G2-M phases are shown. Data represents means of 
three independent experiments ± SD. 1-way ANOVA was performed between vehicle 
and PARPi treated cells *p<0.05. d-f) Expression of d) Trp53, e) Cdkn1a/p21 and f) 
Cdkn2a/p16 in the indicated transformed cells following continuous PARPi treatment. 
Expression of the target genes was normalized against Gapdh (2-ΔCT). Data represents 
means of three independent experiments ± SD. Unpaired t-test performed between 
vehicle and PARPi treated cells *p<0.05, **p<0.01, ***p<0.001. g) Detection of primary 
transformed cells undergoing senescence after 24hrs and 48hrs of PARPi treatment by β-
galactosidase staining. Representative pictures are shown (40X magnification). h) 
Quantification of percentage of β-galactosidase positive cells. Data represents means of 
three independent experiments ± SD. 1-way ANOVA test was performed between 
vehicle and PARPi treated cells for each condition at each time point, ***p<0.001. i) 
Quantification of percentage of Annexin V+/PI+ and Annexin V+/PI- cells upon PARPi 
treatment at 24hrs and 48hrs. Data represents means six independent experiments ± SD. 
1-way ANOVA test was performed between untreated and PARPi treated cells for each 
condition at each time point, ** p<0.01.  
 
Figure 3: AML1-ETO and PML-RARα cells show a defect in HR pathway and 
accumulate DNA damage in response to PARPi treatment.  
a) Immunofluorescence microscopy of γH2AX foci in untreated primary transformed 
mouse cells with the nuclei shown in blue and γH2AX foci in green (representative cells). 
b) Quantification of the percentage of cells with more than 6 γH2AX foci ± SD in 
untreated condition. 1-way ANOVA test was performed between 1) AML1-ETO and 
E2A-PBX, 2) PML-RARα and E2A-PBX, and 3) MLL-AF9 and E2A-PBX (n>3 
**p<0.01, *** p<0.001). c) Time-course analysis of PARPi induced γH2AX and RAD51 
foci by immunofluorescence upon continuous PARPi treatment with the indicated time. 
The panels show the nuclei in blue, γH2AX foci in green and RAD51 foci in red 
(representative cells). d) Quantification of percentage of RAD51 positive cells (> 6 foci) 
0hr (white bars), 6hrs (yellow bars) and 24hrs (red bars) upon PARPi treatment is shown. 
1-way ANOVA test was performed between untreated and 1) 6hr and 2) (n=4 *p<0.05 
***p<0.001). e) The percentage of cells with γH2AX/RAD51 ratio >2 is shown (n=3 
*p<0.05). f) RT-qPCR data of Rad51, Brca1, Brca2, Atm, Mcm9 and Rpa1 expression in 
primary transformed mouse cells. Data represents means of four independent experiments 
± SD.  1-way ANOVA was performed between 1) AML1-ETO and MLL-AF9 and 2) 
PML-RARα and MLL-AF9; *p<0.05, ** p<0.01, *** p<0.001. g) Box-plots showing 
relative microarray expression of RAD51, ATM, BRCA1, BRCA2, MCM9 and RPA1 in 
AML patients carrying the translocation AML1-ETO, PML-RARα (APL) or MLL-
fusions. h) Western blot showing the relative expression levels of RAD51, BRAC2 in 
mouse pre-leukemic cells. Beta ACTIN was used as loading control for quantification to 
generate the indicated relative signal of the bands. i) Colony forming efficiency as 
indicative of DSB repair is shown. Repair efficiency is assessed as the total number of 
bacterial colonies obtained per transformation and expressed as mean ± SEM. 1-way 
ANOVA was performed between indicated samples (n=3) *p<0.05, *** p<0.001. j) 
Percentage of misrepair in panel i). Misrepair is calculated as the fraction of white 
colonies in total (blue and white) colonies, expressed as mean ±SEM. 1-way ANOVA 
was performed between the indicated samples (n=3) *** p<0.001. k) Efficiency of HR-
mediated repair of I-SceI-induced DSB in U2OS/DR-GFP. Cells were transfected with I-
SceI, dsRFP and indicated oncogenes or vector control. Data represents relative repair 
efficiency calculated as a percentage of repair efficiency measured in cells transfected 
with empty vector. All data points represents means of three independent 
experiments+SD. 1-way ANOVA was performed between indicated samples (n=3) 
*p<0.05, ** p<0.01. 
  
Figure 4: HOXA9 modulates the sensitivity to PARPi  
a) Relative colony number of primary transformed cells from wild-type or Hoxa9-/- 
background surviving to PARPi. The number of colonies was counted after seven days 
culture in methylcellulose with PARPi and normalized against the wild-type control. Data 
represents means of at least five independent experiments ± SD. 2-way ANOVA test was 
performed among the data sets: i) wild type vehicle vs Hoxa9-/- vehicle, ii) Hoxa9-/- 
vehicle vs Hoxa9 -/- PARPi **p<0.01, *** p<0.001. b) Representative colony 
morphology as in Figure 4a (Phase contrast magnification 40X). c) Giemsa-
MayGrunwald staining of cells generated with Hoxa9 -/- mice. d) Detection of 
senescence by β-galactosidase staining of cells in panel c. e) Quantification of β-
galactosidase positive cells in percentage upon 48 hrs PARPi treatment. Data represent 
means of two independent experiments ± SD. Unpaired two-tailed t-test vehicle and 
PARPi 48 hrs, *p<0.05 *** p<0.001.f-g) Kaplan-Meier survival curves of C57Bl/6 mice 
transplanted with MLL-AF9 leukemic cells generated in f) wild type (vehicle n=12, 
Olaparib n=12 pooled from three independent experiments) and g) Hoxa9 -/- (vehicle 
n=14, Olaparib n=11 pooled from three independent experiments) background, 
respectively. Log-rank (Mantel-Cox) test was performed between the vehicle and the 
Olaparib group. h) Relative number of colonies of indicated primary transformed cells 
over-expressing HOXA9 in the presence of PARPi. The number of colonies surviving to 
7 days incubation with PARPi was normalized against the vehicle control. Data 
represents means of three independent experiments ± SD. Two-way ANOVA test was 
performed among the data sets: 1) wild type vehicle vs wild type PARPi, 2) wild type 
vehicle vs HOXA9-overexpression PARPi *** p<0.001. i) Colony morphology (phase 
contrast microscopy, magnification 40X). Representative pictures are shown. j) Giemsa-
MayGrunwald staining of primary transformed cells over-expressing HOXA9. k) 
Detection of senescent cells by β-galactosidase staining. l) Quantification of percentage 
of β-galactosidase positive cells upon PARPi treatment for 24 and 48 hrs as in panel k. 
Data represents means of 2 independent experiments ± SD. 1-way ANOVA test was 
performed among the data sets: 1) vehicle vs PARPi 24 hrs, 2) vehicle vs PARPi 48hrs, 
*** p<0.001.  
 
Figure 5: HOXA9 modulates PARPi sensitivity  
a) Immunofluorescence microscopy of PARPi induced (6 hours) γH2AX and RAD51 
foci in wild type and HOXA9 over-expressing cells. Nuclei are shown in blue, γH2AX 
foci in green and RAD51 are shown in red (representative cells). b) The percentage of 1) 
γH2AX positive cells (> 6 foci) in wild-type (filled black bars) and HOXA9 over-
expressing cells (filled red bars) and 2) RAD51 in wild-type (striped black bars) and 
HOXA9 over-expressing cells (striped red bars) is shown. Two-way ANOVA test was 
performed among the data sets: 1) γH2AX in wild-type vs γH2AX in HOXA9 over-
expression, 2) RAD51 in wild-type vs RAD51 in HOXA9 over-expression (n=2 
**p<0.01, ***p<0.001). c) Immunofluorescence microscopy of PARPi induced (6 hours) 
γH2AX and RAD51 foci in MLL-AF9 cells generated in wild type and Hoxa9-/- 
background. Nuclei are shown in blue, γH2AX foci in green and RAD51 are shown in 
red (representative cells). d) The percentage of 1) γH2AX positive cells (> 6 foci) in 
wild-type (filled black bars) and Hoxa9-/- cells (filled green bars) and 2) RAD51 in wild-
type (striped black bars) and Hoxa9-/- cells (striped green bars) is shown. Two-way 
ANOVA test was performed among the data sets 1) γH2AX in wild-type vs γH2AX in 
Hoxa9-/-, 2) RAD51 in wild-type vs RAD51 in Hoxa9-/- (n=3 *p<0.05). e) Gene Set 
Enrichment Analysis (GSEA). Genes associated with homologous recombination 
pathway are enriched in the transcriptional profile of mouse myeloblasts over-expressing 
Hoxa9. NES, normalized enrichment score; FDR, false discovery rate. f) RTq-PCR 
showing expression levels of Rad51 in primary transformed mouse cells over-expressing 
HOXA9. (Expression levels relative to Gapdh, reference control E2A-PBX). Data 
represents means of four experiments ± SD. Unpaired two-tailed t-test was performed 
between wild-type vs HOXA9 over-expression *p<0.05.) g) RT-qPCR data showing 
expression levels of Rad51 in MLL-AF9 cells generated in wild type and Hoxa9-/- 
background. Data represents means of two experiments ± SD. Unpaired two-tailed t-test 
was performed between wild-type vs Hoxa9 KO, *** p<0.001) h) Western blot analysis 
of Rad51 and Brca2 in MLL-AF9 cells generated in wild-type, Hoxa9-/- and β-Catenin-/- 
background. β-ACTIN was shown as loading control. i) Bar chart shows efficiency of 
HR-mediated repair of I-SceI-induced DSB in U2OS cells. Cells were transfected with I-
SceI, dsRFP and HOXA9 expressing/HOXA9 shRNA plasmids. In the case of HOXA9 
over-expression, cells were subjected to 5Gy irradiation 24hrs after transfection. Data is 
normalised to empty vector or scrambled shRNA. Data represents means of 3 
independent experiments ± SD. Unpaired t-test was performed between indicated 
samples (n=3) *p<0.05, ** p<0.01. 
 
Figure 6: Combined PARPi and GSK3i treatment impairs in vivo survival of MLL 
leukemia  
a) Relative number of colonies of pre-leukemic cells surviving to PARPi, LiCl or 
combined PARPi + LiCl treatment. The number of colonies surviving to seven days 
incubation with drug treatment was normalized against the untreated control. Data 
represents means of three independent experiments ± SD. 1-way ANOVA was performed 
among the data sets: 1) vehicle vs PARPi, 2) vehicle vs LiCl, 3) vehicle vs PARPi+ LiCl, 
4) PARPi vs PARPi +LiCl, 5) LiCl vs LiCl +PARPi *** p<0.001. b) RT-qPCR data 
showing expression levels of c-Myb in response to PARPi, LiCl or PARPi+LiCl 
treatment. Data normalized against Gapdh levels in untreated MLL-AF9. Data represents 
means of four independent experiments ± SD. 1-way ANOVA test was performed among 
the data sets as described in Figure 6a *** p<0.001. c) Relative colony number of 
leukemic cells surviving to PARPi, LiCl or combined PARPi + LiCl treatment. The 
number of colonies surviving to seven days incubation with drug treatment was 
normalized against the vehicle control. Data represents means of four independent 
experiments ± SD. 1-way ANOVA was performed among the data sets as described in 
Figure 6a *** p<0.001. d) RT-qPCR data showing expression levels of c-Myb in 
response to PARPi, LiCl or PARPi+LiCl treatment. Data is normalized against Gapdh 
and untreated MLL-AF9. Data represents means of three experiments ± SD. 1-way 
ANOVA test was performed among the data sets as described in Figure 6b ** p<0.01. e) 
Giemsa-MayGrunwald staining of leukemic cells over-expressing HOXA9. f)  The 
percentage of pre-LSC and LSCs undergoing differentiation characterised by morphology 
(upper panel) and NBT-positive cells (lower panel) following treatment with PARPi, 
LiCl or in combination for 4 days. 1-way ANOVA was performed among data set as 
described in Figure 6a. *p<0.05 ***p<0.001. g) Kaplan-Meier survival curves of 
C57Bl/6 mice transplanted with MLL-AF9 leukemic cells pre-treated in liquid culture 
with Olaparib, LiCl or Olaparib+LiCl for three days before transplantation (vehicle n=4, 
Olaparib n=5, LiCl n=5, Olparaib+LiCl n=10). During of in vivo treatment is indicted in 
grey. Log-rank (Mantel-Cox) test was performed between the curves representing the 
vehicle and the treated groups.  p<0.001 for comparison between survival curve 
representing vehicle and survival curve representing Olaparib+LiCl treatment. h-i) 
Relative proliferation of primary human MLL samples from h) AML1 (t11;17) and i) 
AML-2 (t6;11) with  LiCl (8mM), PARPi (1uM Olaparib) or the combined PARPi+LiCl 
treatment. Cells were counted by trypan blue exclusion 5 days after PARPi treatment. 
The data show the fold change in cell number relative to day 0. Data represents means of 
at least two independent experiments ± SD. 1-way ANOVA test was performed among 
the data sets as described in Figure 6a *p<0.05; ** p<0.01; *** p<0.001. j) Giemsa-
MayGrunwald staining of human leukemic cells upon indicated treatments. k) The 
percentage of primary leukemic cells undergoing differentiation characterised by 
morphology (left panel) and NBT positive cells  (right panel) following treatment with 
PARPi, LiCl or combination for 5 days. 1-way ANOVA was performed among the data 
sets as described in Figure 6a. **p<0.01 ***p<0.001. l) Results of in vivo imaging of 
disease progression of mice transplanted with AML1 primary human leukemic cells 
carrying luciferase reporter upon treatments. Left panel: Quantification of tumour burden 
measured as photon per second*10E+03 in NSG mouse 28 days after transplantation with 
primary human MLL cells. Right: Fold change in tumor burden between Day 28 and Day 
21 after the transplant. Low level of tumor burden was detectable at Day 21. 1-way 
ANOVA was performed between vehicle and treated group. ** p<0.001. m) Kaplan-
Meier survival curves of NSG mice transplanted with AML1 leukemic cells (vehicle n=6, 
Olaparib n=6, LiCl n=6, Olparaib +LiCl n=6). Duration of in vivo treatment is indicted in 
grey. Log-rank (Mantel-Cox) test was performed between the curves representing the 
vehicle and the treated groups. **p<0.01 for comparison between survival curve 
representing vehicle and the survival curve representing Olaparib+LiCl treatment.  
 
 
 
 
Supplementary Figure 1 (data related to Figure 1): PARPi targets AML1-ETO and 
PML-RARα leukemic cells in vitro and in vivo.  
a) Non-linear regression dose response curve of Olaparib treatment in normal mouse 
bone marrow c-Kit+ cells grown in methylcellulose for 7 days. Data represents means of 
three independent experiments ± SD. The EC50, the half maximal effective 
concentration, of Olaparib for the cells is indicated. b) Colony morphology of c-Kit+ 
normal mouse bone marrow cells (Phase contrast microscopy magnification 40X). 
Representative pictures are shown. c) Absolute colonies number of leukemic cells 
surviving to Olaparib treatment corresponding to Fig. 1a. Data represents means of six 
independent experiments ± SEM. d) Non-linear regression dose response curve of 
leukemic cells as indicated grown in methylcellulose for 7 days with escalating doses of 
PARPi. Data represents mean of three independent experiments are shown. The EC50 of 
Olaparib for the cells is indicated. e) Relative colonies number of leukemic cells 
surviving to PARPi, Veliparib. The number of colonies surviving to seven days 
incubation with Veliparib treatment was normalized against the untreated control. Data 
represents means of three independent experiments ± SD. unpaired two-tailed t-test was 
performed between vehicle and Veliparib treated cells for each condition ***p<0.001. f) 
Representative morphology of colonies indicated in Supplementary Fig. 1e (phase 
contrast microscopy, magnification 20X). g) Efficiency of Parp1 Knockdown (KD) in 
NIH3T3 cells transduced with retroviral vectors expressing shRNA targeting against 
mouse Parp1. RT-qPCR data showing expression of Parp1 in NIH3T3 transduced with 
sh-mParp1. Data represents means of two independent experiments ± SD. 1-way 
ANOVA test was performed between empty vector and 1) sh-Parp1-A and 2) sh-Parp1-D 
***p<0.001. h) RT-qPCR showing Parp1 KD efficiency in primary cells transformed by 
the indicated fusion proteins. Data represents means of three independent experiments ± 
SD. 1-way ANOVA test was performed between empty vector and 1) sh-Parp1-A and 2) 
sh-Parp1-D *p<0.05, **p<0.01, ***p<0.001. i) Absolute colonies numbers from the 
indicated primary transformed cells after shRNA-mediated Parp1 KD, corresponding to 
Fig. 1c. Data represents means of more than three independent experiments ± SD. j-l) 
Flow cytometry analysis of bone marrow, spleen and liver harvested from sick mice 
transplanted with j) Kasumi, k) NB4-LR2 cell and l) THP1 respectively confirming level 
of engraftment. m-o) Giemsa-MayGrunwald staining of cells harvested from bone 
marrow, spleen or tumor of sick mice succumbed transplanted with m) Kasumi, n) NB4-
LR2 and o) THP1 respectively. Bright field microscopy (40x). Representative pictures 
are shown. p) Non-linear regression dose response curve of primary AML patient cells to 
Olaparib. Primary patients cells were treated with PARPi for 5 days. Data represents 
means of three independent experiments ± SD.  q) EC50 of MLL, APL and AML-ETO 
primary patient samples to Olaparib. 1-way ANOVA was performed between 1) MLL 
and APL patients samples 2) MLL and AML1-ETO patients samples. ** p<001.  
 
Supplementary Figure 2 (data related to Figure 2):   PARPi induces differentiation, 
senescence, and apoptosis of AML1-ETO and PML-RARα leukemic cells  
a) Proliferation of pre-leukemic cells in the presence and absence of PARPi in 
methylcellulose at indicated time point.  b) Giemsa-MacGrunwald staining of primary 
transformed cells with PARPi treatment at indicated time points. Representative pictures 
are shown. c) Percentage of differentiated cells counted according to morphology from 
figures shown in panel (b). Unpaired two-tailed t-test was performed between cells 
treated with vehicle or PARPi for 2, 4 and 6 days. *p<0.01, ***p<0.001. d) Percentage of 
NBT positive cells. Data represents means of three independent experiments ± SD. 
Unpaired two-tailed t-test was performed between cells treated with vehicle or PARPi for 
2, 4 and 6 days. *** p<0.001. e) Representative cell cycle profiles related to Fig. 2c. f) 
Representative FACS profile (Annexin V/PI) of pre-leukemic cells treated with PARPi 
related to Fig. 2i.  g) Detection of senescent cells by β-galactosidase staining in human 
leukemic cell lines after 72hrs of PARPi treatment. h) Quantification of percentage of β-
galactosidase positive in human leukemic cells following PARPi treatment. Data 
represents means of two independent experiments ± SD.  Unpaired t-test was performed 
between vehicle and PARPi treated cells, ***p<0.001. i) Quantification of apoptotic cells 
in human leukemic cell lines in percentage upon 4 days PARPi treatment. Data represents 
means of four independent experiments, ± SD. Unpaired two-tailed t-test was performed 
between vehicle and PARPi *** p<0.001. j) Giemsa-Mayrunwald staining of human 
primary AML cells upon 1μM Olaparib treatment for 5 days. The red arrow indicates the 
differentiated cells. k) Quantification of morphologically differentiated cells relating to 
panel 2j.  Data represents means of two independent experiments ± SD. Unpaired t-test 
was performed between cells treated with vehicle and PARPi **p<0.01. l) Percentage of 
NBT positive cells after PARPi treatment for 5 days. Data represents mean of three 
independent experiments ± SD. Unpaired t-test test was performed between cells treated 
with vehicle and PARPi *p<0.05,  *** p<0.001. 
 
Supplementary Figure 3 (data related to Figure 3): AML1-ETO and PML-RARα 
cells show a defect in HR pathway and accumulate DNA damage in response to 
PARPi treatment.  
a) Western blot showing endogenous PARP1 co-immunoprecipitates with APLF 
(positive control ) but not the oncofusion proteins  in transfected 293T cells.  b-e) RT-
qPCR showing the effect of Parp1 KD on b) AML-1-ETO, c) PML-RARα, d) MLL-AF9 
and e) E2A-PBX target genes. Data represents means of two independent experiments  ± 
SD. 1-way ANOVA test was performed between 1) Scrambled and shParp1-A; 2) 
Scrambled and shParp1-D.  *p<0.05, **p<0.01. f) The percentage of cells with >10 
γH2AX foci± SEM in untreated condition is shown, and exhibits similar results by 
counting >6  γH2AX foci in Fig. 3b. 1-way ANOVA was performed between: 1) AML1-
ETO and E2A-PBX, 2) PML-RARα and E2A-PBX, 3) MLL-AF9 and E2A-PBX, 4) 
AML1-ETO and MLL-AF9, 5) PML-RARα and MLL-AF9 (n=7, *p<0.05, ** p<0.01, 
***p<0.001). g-j) Time-course analysis of PARPi induced γH2AX and RAD51 foci by 
immunofluorescence microscopy in g) AML1-ETO, h) PML-RARα, i) MLL-AF9 and j) 
E2A-PBX cells . The panels show the nuclei in blue, γH2AX foci in green and RAD51 
foci in red. k). The percentage of γH2AX positive cells (> 6 foci) 0 (white bars), 6 
(yellow bars) and 24 hrs (red bars) upon PARPi treatment is shown. 1-way ANOVA was 
performed between untreated and 1) 6hr and 2) 24hr (n=4 *p<0.05, ***p<0.001). l) The 
figure shows the percentage of RAD51 positive cells (>10 foci), 0 (white bars), 6 (yellow 
bars) and 24hrs (red bars) upon PARPi treatment. 1-way ANOVA test was performed 
between: 1) untreated and 6hrs and 2) untreated and 24hrs post treatment (n=4, 
***p<0.001). Consistent results were obtained by counting >6 Rad51 foci in Fig. 3d.  m) 
Cell cycle analysis of indicated primary transformed cells treated with vehicle or PARPi 
for 6hrs (left) and 24hrs (right). n) Immunofluorescence microscopy for γH2AX foci in 
untreated human cells with nuclei in blue (DAPI) and γH2AX foci in green 
(representative cells). o) The percentage of cells with >6 γH2AX foci ± SD in untreated 
condition. 1-way ANOVA was performed between:  1) Kasumi and THP1 and 2) NB4 
and THP1 ** p<0.01 p) Time-course analysis of PARPi induced γH2AX and RAD51 
foci by immunofluorescence microscopy in human leukemic cell lines. The panels show 
the nuclei in blue, γH2AX foci in green and RAD51 foci in red (representative cells). q) 
The percentage of RAD51 positive human cells (> 6 foci) 0 (white bars), 6 hrs (yellow 
bars) and 24 hrs (red bars) upon PARPi treatment. 1-way ANOVA test was performed 
between untreated and 6hr (n=4 **p<0.01). r) The percentage of cells with 
γH2AX/RAD51 ratio >2, Unpaired t-test was performed with ** p<0.01.  s) Box-plot 
showing normalized expression of DNA repair-associated genes in AML patient samples 
from Verhaak et al., Haematologica 2009. AML1-ETO n=37, APL n=25, MLL n=35). 
*p<0.05, **p<0.01, ***p<0.001, NS=Not Significant, p values were calculated using 
unpaired t-Test.   
 
Supplementary Figure 4 (data related to Figure 4): HOXA9 modulates the 
sensitivity to PARPi 
a) RT-qPCR data showing expression of human HOXA9 in U937 cell lines carrying Zinc 
(Zn)-inducible AML1-ETO or PML-RARα 6hrs after the induction. . Data represents 
means of two independent experiments ± SD. 2-way ANOVA test was performed 
between untreated and  Zinc induced cells (**p<0.01).   b) RT-qPCR data showing 
expression of mouse Hoxa9 in primary transformed cell line expressing inducible MLL-
AF9-ER after tamoxifen withdrawal at indicated time points. Data represents means of 
three independent experiments ± SD. 1-way ANOVA test was performed between Day 0 
(untreated) and  Day 3, Day 0 and Day 5 (*p<0.05, *p<0,001). c) Normalized expression 
of HOXA9 in AML patient samples from Verhaak et al., Haematologica 2009 (Left) and 
Valk et al., NEJM 2004 (Right), ***p<0.001, NS=Not Significant, p-values were 
calculated using unpaired t-test.  d) Semi-quantitative PCR showing the genotype of cells 
generated in wild type and Hoxa9-/- background. e) Absolute colony number of primary 
transformed cells generated in wild-type or Hoxa9-/- background surviving to PARPi. 
Data represent means of five independent experiments ± SEM, corresponding to data in 
Fig. 4a.  f) Flow cytometry analysis (c-Kit/Gr1 and c-Kit/Mac1) of primary transformed 
cells before and after PARPi treatment.  g) Kaplan-Meier survival curves of C57Bl/6 
mice serially transplanted with MLL-AF9 cells generated in Hoxa9 -/- (bold black line, 
n=5) and wild type (bold red line, n=3) background. The leukemic cells harvested from 
mice succumbed with leukemia (primary recipients) were transplanted in C57Bl/6 
recipient mice (secondary transplants, dotted lines, n=9 and n=3). h) Flow cytometry 
analysis (CD45.1/CD45.2, Gr1/c-Kit, Gr1/Mac1) of bone marrow harvested from mice 
treated as indicated. wild type (left) and Hoxa9 -/-  (right).  Engrafted cells were labelled 
by CD45.1. i) Absolute colony number of primary transformed cells over-expressing 
HOXA9 surviving to PARPi, corresponding to data shown in Figure 4h. Data represent 
means of three independent experiments ± SEM. j) RT-qPCR data showing expression of 
Hoxa9 and their respective oncogenes in transformed mouse cells before and after Hoxa9 
over-expression. Data represents means of two independent experiments ± SD. Unpaired 
two tailed t-test was performed between wild type vs Hoxa9 over-expression n=4, 
*p<0.05, ** p<0.01, *** p<0.001. 
 
Supplementary Figure 5 (related to Figure 5): HOXA9 modulates PARPi sensitivity 
a-b) Gene Sets Enrichment Analysis (GSEA). Gene sets associated with DNA repair (a) 
and double strand break repair (b) are enriched in the transcriptional profile of mouse 
myeloblasts over-expressing HOXA9. c) RT-qPCR of DDR genes in MLL-AF9 wild 
type and MLL-AF9 Hoxa9 KO cells. Gene expressions in MLL-AF9 wild-type were 
normalized to 1.  Data represents means of two independent experiments ± SD. 1-way 
ANOVA test was performed between untreated and  PARPi treated cells (***p<0.001).   
 
Supplementary Figure 6 (data related to Figure 6): Combined PARPi and GSK3i 
treatment impairs in vivo survival of MLL leukemia  
a) Non-linear regression dose response curve of GSK3i (LiCl) in c-Kit+ normal mouse 
bone marrow cells grown in methylcellulose. Colony number was acquired after 7 days 
of culture. Data represents means of three independent experiments±SD. EC50 (50% of 
maximal effective concentration) are indicated in the figure. b-c) Absolute colony 
number of b) pre-LSC c) LSC surviving to PARPi, LiCl or combined PARPi+LiCl 
treatment. Relative number of colony is shown in Figure 6a and c. Data represents means 
of three independent experiments ± SEM. 1-way ANOVA test. **p<0.01, ***p<0.001. 
Data represents means of four independent experiments±SEM. 1-way ANOVA test 
***p<0.001.  d) Flow cytometry analysis (CD45.1/CD45.2, c-kit/Gr1, Gr1/Mac1) of 
bone marrow harvested from C57Bl6 mice transplanted with CD45.1 positive MLL-AF9 
cells. e) Giemsa-MayGrunwald staining of cells harvested from bone marrow of sick 
animals with indicated treatments. f) Relative proliferation of human leukemic cells 
THP1 to LiCl, PARPi or combined PARPi+LiCl treatment. Cells were counted on day 5 
after treatment by trypan blue exclusion. The data show the fold change in cell number 
relative to day 0. Data represents means of at least two independent experiments ± SD. 1-
way ANOVA Test was performed among the data sets: 1) untreated vs PARPi, 2) 
untreated vs LiCl, 3) untreated vehicle vs PARPi+ LiCl, 4) PARPi vs PARPi +LiCl, 5) 
LiCl vs LiCl +PARPi ** p<0.01; *** p<0.001. g) Giemsa-MayGrunwald staining of 
human THP1 cells with indicated treatments. h) Pictures showing the tumor burden of 
each treatment group that are visualized and quantified in Figure 6l.  i) Flow cytometry 
analysis (CD45/CD33) of bone marrow harvested from sick NSG mice transplanted with 
primary AML1 cells undergone indicated treatments. j) Giemsa-MayGrunwald staining 
of cells harvested from bone marrow of sick mice with indicated treatment.  
 
Supplementary Figure 7: Proposed models for PARPi treatments in different AML 
subtypes driven by oncogenic transcription factors.   
AML1-ETO and PML-RARα suppress the expression of DDR gene and HR efficiency, 
which make them sensitive to PARPi treatment.  In contrast, leukemia driven by MLL-
fusion expressing a high level of HR genes including HOXA9 is refractory to PARPi.  
Inactivation of HOXA9 by genetic mean or GSK3i can re-sensitize MLL leukemia to 
PARPi, and suppresses disease development. 
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Supplementary Figure 7: Proposed Model 
  
 
 
 
Table S1: Table, related to Figure 1g, summarising the characteristics of NSG mice succumbed with Kasumi 
driven disease 
 Vehicle (n=6) Olaparib (n=5) Normal* 
Disease Latency (days; 
median) 55 102 N/A 
Spleen (g) 0.0873±0.0409 0.1630±0.1198 0.03997±0.0056
Liver (g) 1.843±0.1330 1.999±0.3720 1.037±0.1050
BM Engraftment (%) 49.22±21.47 41.35±27.73 N/A 
Hematopoietic Spleen 
Engraftment (%) 39.84±21.93 48.68±33.71 N/A 
Hematopoietic Liver 
Engraftment (%) 42.76±30.9 41.68±26.19 N/A 
CBC WBC (109/L) 2.5± 0.8485 2.9± 2.832 5.238±3.763
CBC RBC (1012/L) 6.68±0.396 6.835±1.328 7.235±0.8716
CBC Platelets (109/L) 349±39.6 514.8±245.2 467.9±231.7
N/A: not applicable 
* Normal: normal NSG mice.  Data collected from 3 animals 
 
  
  
 
Table S2: Table, relating to Figure 1h, summarising the characteristics of NSG mice succumbed with NB4-LR2 
driven disease 
 Vehicle (n=5) Olaparib (n=10) Normal* 
Disease Latency (days; 
median) 39 51 N/A 
Spleen (g) 0.1216±0.0232 0.5226±0.5279 0.03997±0.0056
Liver (g) 2.26±0.401 2.415±1.844 1.037±0.1050
BM Engraftment (%) 30.94±23.11 40.27±23.73 N/A 
Hematopoietic Spleen 
Engraftment (%) 22.8±25.13 33.39±25.3 N/A 
Hematopoietic Liver 
Engraftment (%) 47.64±19.68 58.99±27.07 N/A 
CBC WBC (109/L) 3.875± 3.288 2.322± 1.177 5.238±3.763
CBC RBC (1012/L) 8.14±3.857 7.576±3.309 7.235±0.8716
CBC Platelets (109/L) 442.3±177.9 406.3±43.46 467.9±231.7
N/A: not applicable 
* Normal: normal NSG mice.  Data collected from 3 animals. 
  
  
Table S3: Table, relating to Figure 1i, summarising the characteristics of NSG mice succumbed with THP1 
driven disease 
 Vehicle (n=6) Olaparib (n=6) Normal 
Disease Latency (days; 
median) 81 81 N/A 
Spleen (g) 0.108±0.0146 0.0822±0.0301 0.03997±0.0056
Liver (g) 1.28±0.147 1.31±0.153 1.037±0.1050
BM Engraftment (%) 3.266±2.153 30.7±33.27 N/A 
Hematopoietic Spleen 
Engraftment (%) 8.831±5.679 8.53±6.946 N/A 
Hematopoietic Liver 
Engraftment (%) 46.48±43.05 27.81±31.79 N/A 
CBC WBC (109/L) 4.1±3.69 6.18±4.22 5.238±3.763
CBC RBC (1012/L) 7.653±0.611 8.526±1.575 7.235±0.8716
CBC Platelets (109/L) 183.83±70.25 132.2±27.58 467.9±231.7
N/A: not applicable 
* Normal: normal NSG mice.  Data collected from 3 animals. 
 
 
 
 
  
  
Table S4: Genes associated with GO:0000724: double-strand break repair via homologous recombination 
analysis enriched in gene ontology (GO) analysis of gene expression in human leukemia with MLL-
rearrangement compared to APL and AML1-ETO subtypes (column 1) and HOXA9 responsive genes (column 
2) in published datasets.  Highlighted are DDR genes commonly activated by MLL fusions and Hoxa9.   
MLL-rearrangement HOXA9
RAD51 RAD51
MCM9 MCM9
ATM ATM
BLM BLM
BRCA1 BRCA1
BRCA2 BRCA2
CHEK1 CHEK1
HUS1 HUS1
MRE11A MRE11A
PARPBP PARPBP
RAD51C RAD51C
RPA1 RPA1
RAD50 ERCC4
MORF4L1 NABP2
TERF2IP PPP4C
NBN RAD21L1
H2AFX RAD51B
NABP2 RAD51D
RBBP8 RAD52
MDC1 RAD54B
RAD51AP1 RTEL1
PSMD14 SIRT6
PALB2 SMC6
RPA2 TEX15
LIG1 TONSL
RPA3 XRCC3
SHFM1
SMC5
UBE2N
YY1
 
 
 
 
 
  
  
Table S5 Table, relating to Figure 4f, summarising the characteristics of C57bl6 mice succumbed with MLL-
AF9 wild-type driven leukemia 
 Vehicle (n=12) Olaparib (n=12) Normal* 
Disease Latency (days; 
median) 31 34 N/A 
Spleen (g) 0.7968±0.39 0.9309±0.3767 0.1130±0.03430
Liver (g) 3.486±1.71 4.204±1.425 1.331±0.2650
BM Engraftment (%) 95.99±5.054 93.30±9.257 N/A 
Hematopoietic Spleen 
Engraftment (%) 90.25±8.872 86.85±13.12 N/A 
Hematopoietic Liver 
Engraftment (%) 94.22±3.393 93.16±6.838 N/A 
CBC WBC (109/L) 26.87±35.61 26.03±34.48 19.32±3.177
CBC RBC (1012/L) 5.573±0.7508 5.735±3.426 8.620±0.3385
CBC Platelets (109/L) 190±68.02 203±255.1 357.8±83.54
N/A: not applicable 
* Normal C57Bl6 mice: Data collected from 3 mice 
  
  
Table S6: Table relating to Figure 4g, summarising the characteristics of C57Bl6 mice succumbed with MLL-
AF9-Hoxa9 KO driven leukemia 
 Vehicle (n=14) Olaparib (n=11) Normal* 
Disease Latency (days; 
median) 32 67 N/A 
Spleen (g) 0.5429±0.1810 0.4337±0.1559 0.1130±0.03430
Liver (g) 2.127±0.5528 1.696±0.1262 1.331±0.2650
BM Engraftment (%) 61.3±28.64 82.06±18.95 N/A 
Hematopoietic Spleen 
Engraftment (%) 50.62±33.78 65.4±33.45 N/A 
Hematopoietic Liver 
Engraftment (%) 64.02±23.34 62.18±38.26 N/A 
CBC WBC (109/L) 41.4±47.8 53.93±51.06 19.32±3.177
CBC RBC (1012/L) 5.187±1.95 4.153±2.066 8.620±0.3385
CBC Platelets (109/L) 223±83.45 227±166 357.8±83.54
N/A: not applicable 
* Normal C57Bl6 mice: Data collected from 3 mice 
 
  
  
Table S7: Table, relating to Figure 6g, summarising the characteristics of C57Bl6 mice succumbed with MLL-
AF9 wild-type driven leukemia. 
 Vehicle (n=4) Olaparib (n=5 LiCl (n=5) Olaparib+LiCl (n=10) Normal* 
Disease Latency (days; 
mean) 41.5 45.8 38.2 N/A** N/A 
Spleen (g) 1.115±0.3960 1.218±0.3266 1.108±0.4018 N/A 0.1130±0.03430
Liver (g) 2.483±0.4211 2.868±0.4089 2.625±0.6598 N/A 1.331±0.2650
BM Engraftment (%) 95.03±2.2937 80.23±23.70 97.23±1.408 N/A N/A
Hematopoietic Spleen 
Engraftment (%) 86.47±3.523 65.07±43.46 91.28±4.623 N/A N/A 
Hematopoietic Liver 
Engraftment (%) 92.97±3.175 76.5±19.21 93.73±5.5508 N/A N/A 
CBC WBC (109/L) 26.87±35.61 26.03±34.48 24.03±28.11 N/A 19.32±3.177
CBC RBC (1012/L) 5.573±0.7508 5.735±3.426 5.29±2.578 N/A 8.620±0.3385
CBC Platelets (109/L) 190±68.02 203±255.1 135.8±89.68 N/A 357.8±83.54
N/A: not applicable 
* Normal C57Bl6 mice: Data collected from 5 mice 
** No disease latency because no animal comes down with disease. 
  
  
Table S8: Table, relating to figure 6m, summarising the characteristics of NSG mice succumbed to leukemia 
driven by primary AML1 cells treated with Olaparib, Li diet or combination therapy in vivo. 
 Vehicle (n=6) Olaparib (n=6) Li diet (n=6) Olaparib+Li diet (n=6) Normal* 
Disease Latency 
(days; median) 59 60 45 N/A** N/A 
Spleen (g) 0.076±0.030 0.136±0.029 0.133±0.060 N/A 0.03997±0.0056
Liver (g) 1.20±0.157 1.30±0.134 1.27±0.091 N/A 1.037±0.1050
BM Engraftment 
(%) 57.98±30.49 53.23±23.21 28.72±15.19 N/A N/A 
Hematopoietic 
Spleen 
Engraftment (%) 
11.30±7.885 2.733±4.166 1.760±3.266 N/A N/A 
Hematopoietic 
Liver 
Engraftment (%) 
42.65±22.61 23.20±20.61 16.93±17.75 N/A N/A 
CBC WBC (109/L) 3.000±2.160 3.950±3.265 5.267±7.450 N/A 5.238±3.763
CBC RBC (1012/L) 7.978±0.659 6.652±1.908 5.960±2.003 N/A 7.235±0.8716
CBC Platelets 
(109/L) 307.8±160.9 393.2±293.6 314.3±274.1 N/A  467.9±231.7 
N/A: not applicable 
* Normal NSG mice: Data collected from 6 mice 
** No disease latency and engraftment data because no animal comes down with disease.   
 
 
  
  
 
Table S9: List of antibodies (The antibodies provided as gift were mentioned in materials and methods). 
Antibody Supplier Catalog number Application Dilution
Actin-HRP Scbt Sc-1616 Western Blot 1:1000
Phospho-y H2AX 
(ser139) 
Upstate  05-636 Immunofluorescence 1:200
Rad51 Scbt Sc-8349 Western Blot 1:500
Rad51 Scbt Sc-8349 Immunofluorescence 1:100
PARP1 Cell signaling #9542S Western Blot 1:1000
FLAG (M2) Sigma F1804 Western Blot
Immunoprecipitation 
1:5000
1ug 
 
  
  
 
Table S10.  List of Primers sequences*  
Primer Sequence Application 
mouse Rad51 F aagttttggtccacagcctattt qRT-PCR
mouse Rad51 R cggtgcataagcaacagcc  qRT-PCR 
mouse p53 F ctctcccccgcaaaagaaaaa qRT-PCR
mouse p53 R cggaacatctcgaagcgttta qRT-PCR
mouse p21 F ccacagcgatatccagacattc qRT-PCR 
mouse p21 R gcggaacaggtcggacat qRT-PCR 
mouse Xrcc2 F ggaaaggcccacatgtgagt qRT-PCR
mouse Xrcc2 R ggatcgtttgtgacataggcatt qRT-PCR 
mouse Parp1 F gctttatcgagtggagtacgc qRT-PCR 
mouse Parp1 R ggagggagtccttgggaatac qRT-PCR
mouse Gapdh F gtatgactccactcacggcaaa qRT-PCR 
mouse Gapdh R ttcccattctcggccttg qRT-PCR
mouse Brca1 F aagagacagtaactaagccaggt qRT-PCR 
mouse Brca1 R ggggcggtctgtaacaattcc qRT-PCR 
mouse Brca2 F atgcccgttgaatacaaaagga qRT-PCR
mouse Brca2 R accgtggggcttatactcaga qRT-PCR
mouse c-Myb F agaccccgacacagcatcta qRT-PCR
mouse c-Myb R ccgggccgaagagatttctg qRT-PCR 
human HOXA9 F gccggccttatggcattaa qRT-PCR (Taqman) 
human HOXA9 R cagggacaaagtgtgagtgtcaa qRT-PCR (Taqman) 
human HOXA9 probe FAM-tgaaccgctgtcggccagaagg-TAMRA qRT-PCR(Taqman) 
mouse HoxA9 F ccgaacaccccgacttca qRT-PCR (Taqman) 
mouse HoxA9 R ttccacgaggcaccaaaca qRT-PCR (Taqman) 
mouse HoxA9 probe FAM-tgcagcttccagtccaaggcgg-TAMRA qRT-PCR (Taqman) 
mouse Gapdh Taqman primers 
and probe 
Applied Biosystem #4331182 qRT-PCR (Taqman) 
human GAPDH Taqman primers 
and probe 
Applied Biosystem #402869 qRT-PCR (Taqman) 
mouse p16F cgtgagggcactgctggaag qRT-PCR
mouse p16R accagcgtgtccaggaagcc qRT-PCR 
mouse Mcm9F ggtcaggtgtttgagtcctatg qRT-PCR 
mouse Mcm9R ggtcaggtgtttgagtcctatg qRT-PCR
Mouse AtmF ccagctttttgatgcagatacca qRT-PCR 
Mouse AtmR ccagctttttgatgcagatacca qRT-PCR 
Mouse Rpa1F acatccgtcccatttctacagg qRT-PCR
Mouse Rpa1R ctccctcgaccagggtgtt  qRT-PCR 
mouse HoxA9 wt F cacaaaggggctctaaatcc  Genotype PCR 
mouse HoxA9 wt R agcacatacagccaatagcg Genotype PCR 
mouse HoxA9 KO F aaggcaggtcaagatctccga  Genotype PCR 
mouse HoxA9 KO R tcgccttcttgacgagttctt Genotype PCR 
Mouse Bcl2 F ggggtcatgtgtgtggagag qRT-PCR
Mouse Bcl2 R gcatgctggggccatatagt qRT-PCR 
Mouse Tgm2 F agagtgtcgtctcctgctct qRT-PCR 
Mouse Tgm2 R gtagggatccagggtcaggt qRT-PCR
Mouse Id1 F gagtctgaagtcgggaccac qRT-PCR 
mouse Id1 R ctggaacacatgccgcct qRT-PCR 
mouse Wnt16 F ccagtacggcatgtggttca qRT-PCR
mouse Wnt16 R gacattaacttggcgacagcc qRT-PCR 
Mouse Ccl1 F gcaagagcatgcttacggtc qRT-PCR 
Mouse Ccl1 R tagttgaggcgcagctttct qRT-PCR
* qRT-PCR primers are for SYBR-Green except those mentioned (Taqman).  Genotype PCR were performed by conventional 
PCR. 
 
